A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. - Wikidata - wikimedia - TriplyDB

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33336492

about

Scrutinizing the scaffolds of marine biosynthetics from different source organisms: Gram-negative cultured bacterial products enter center stage Marine-derived anticancer agents in clinical trials.Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer's Disease Phase IIa and Expanded Access Trials.Cancer chemopreventive and anticancer evaluation of extracts and fractions from marine macro- and microorganisms collected from Twilight Zone waters around Guam.Protein kinase C inhibitors as novel anticancer drugs.Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells.Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Bryozoa, Mollusca, Echinodermata and Urochordata.Bryostatin-1: a novel PKC inhibitor in clinical development.Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.Marine-derived angiogenesis inhibitors for cancer therapy.The medicinal potential of promising marine macrolides with anticancer activity.Protein kinase C and its inhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example.Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc gamma -receptors.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.

P2860

Q26860194-A478C355-E7B5-43F0-8146-081CE08A3ED7 Q30969641-DCBDDE64-881C-447E-9E83-75E422824727 Q33708951-6DEB7C51-53FF-4845-B56C-63DACBA50DE7 Q33743718-0EF0D03A-E237-4FBB-A1E3-C0B54D0B60E7 Q34481881-B25CC9F2-D3D6-48DB-A91B-A06E6EA2D341 Q34534299-3E0121DB-9FCA-4206-8875-B9DCC5B74599 Q35540360-9519F7E7-C7F5-418C-863E-3529E05296C0 Q35634829-FD1262EB-CBDE-4E74-B87D-80DE38E1B1F9 Q35733482-EED8BB17-11FF-4BDE-80F3-AB508CDC8C39 Q36994177-B2CCA20A-6E0B-4308-A216-C88EC908B39D Q37837738-7A315661-BDBB-4A59-AE76-918AB9AE6DC9 Q38150917-A02300E9-2E9A-40A6-9450-DA74468A2DA1 Q42026336-AECC051D-24BA-4DAD-BAA8-20C55CF27AFB Q55365628-D9ADE16D-3CDF-4FD4-9150-BC5CED639214

P2860

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33336492

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@ast

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@en

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@nl

type

label

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@ast

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@en

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@nl

prefLabel

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@ast

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@en

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

@nl

P1433

Q33336492-144F8F5D-E371-45DB-9E55-CF5761E8F165

P1476

Q33336492-88FC82B4-5F43-4532-AC2E-495BC870DE1F

P2093

Q33336492-019E6D07-B289-4CC4-9B58-D647E8080235

Q33336492-1ADBD0B6-5F15-47A3-B020-C403AC0A8A57

Q33336492-22A540AF-3286-4477-956B-97CB0D7C05AC

Q33336492-9D592C6C-8F47-4A33-BDBE-146394B1441C

Q33336492-AD0245B7-3670-4DC0-99F7-5461B73E6CA8

Q33336492-AD1DA177-7D8E-4B0B-A662-851403436496

Q33336492-CB81CEB9-8598-4982-B302-8C0698ECA31C

P2860

Q33336492-020B9DE9-3CD1-489A-8415-9E7D8041F9B0

Q33336492-034CF2E1-0D47-4A08-928D-1FC06B1E6BFA

Q33336492-0E583C13-271D-41E4-A1FF-CDFFB91E9457

Q33336492-10707A20-9BC5-43C3-AF23-31353C770B64

Q33336492-1AF768A4-E404-42E8-BDC0-2D1344615193

Q33336492-1E32757C-AF28-4E4C-8A92-D4353CF6FE12

Q33336492-20556BD5-4744-4487-903A-47348C251897

Q33336492-2057DE8E-B9F5-48BC-A7FD-AB3D28220E43

Q33336492-2EF23843-4442-4D95-B0FB-EBC2A4D3DE25

Q33336492-3518D905-3D59-4CA6-86DD-2CD9D1562C08

P2888

Q33336492-88D3824F-09EB-428D-91E5-96A668450548

P304

Q33336492-1949E60B-71C2-47F0-ADCD-6AFB57E48598

P31

Q33336492-9646B60A-D4F1-4E93-AEDE-C4841282DE64

P356

Q33336492-F469B179-7CD6-4FF6-9196-212D067F4767

P407

Q33336492-3D2F5906-1CCB-4671-9BB0-9FDA8BF0F849

P433

Q33336492-96D271E1-3186-422C-962B-24995994158A

P478

Q33336492-5A03FBAC-50DA-4E0C-903E-E32F81333727

P50

Q33336492-1AB8F64F-EC90-4D52-98A6-498547FC56E7

Q33336492-4ABEDECA-797A-4095-9E91-CD5392DB3C30

Q33336492-C221D59D-E2C0-43D0-B7B2-91A8FC0468CB

P577

Q33336492-9B6CBE9D-D19F-47D3-8B58-EAF36698A020

P5875

Q33336492-8ED41221-417E-4D67-B82A-49A17296B7C7

P6179

Q33336492-FDAAC73E-3CC2-48A1-B9C9-6A82C9E1DDFD

P698

Q33336492-EA7C5687-BB91-4D4D-B165-622C715C5308

P921

Q33336492-35A81B16-4759-4BF3-B564-2983FDE03B0F

Q33336492-D53F1E98-1D11-4ABD-9EC5-FC2EDADDBF59

P932

Q33336492-A8A814B3-5EFA-4AE3-92D0-741F9DEB7ABA

P356

P1433

British Journal of Cancer

P1476

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

@en

P2093

A Robbins

http://www.w3.org/2001/XMLSchema#string

A T McGown

http://www.w3.org/2001/XMLSchema#string

B W Hancock

http://www.w3.org/2001/XMLSchema#string

Cancer Research Campaign Phase I/II Committee

http://www.w3.org/2001/XMLSchema#string

G Halbert

http://www.w3.org/2001/XMLSchema#string

M Ranson

http://www.w3.org/2001/XMLSchema#string

M Soukop

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

Reporting results of cancer treatment

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

Studies and perspectives of protein kinase C.

Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study.

A phase II study of bryostatin 1 in metastatic malignant melanoma.

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.

P2888

P304

465-469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1054/BJOC.2000.1624

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Fiona Blackhall

Gordon C. Jayson

P577

2001-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12070285

http://www.w3.org/2001/XMLSchema#string

P6179

1015301280

http://www.w3.org/2001/XMLSchema#string

P698

11263437

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

2363763

http://www.w3.org/2001/XMLSchema#string